Table 2 Multivariable analysis of hazard ratio (HR) with 95% confidence interval (CI) of esophageal adenocarcinoma and esophageal squamous-cell carcinoma according to exposure to androgen deprivation therapy (ADT).

From: Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer

 

Esophageal adenocarcinoma

Esophageal squamous-cell carcinoma

No

Yes

HR (95% CI) Crude

HR (95% CI) Adjusted

No

Yes

HR (95% CI) Crude

HR (95% CI) Adjusted

All men

101,659

75

  

101,708

26

  

No ADT

84,112

62

1.00 (Reference)

Ref

84,152

22

Ref

Ref

All ADTs

17,547

13

1.25 (0.67–2.35)

1.17 (0.60–2.32)

17,556

4

1.03 (0.34–3.17)

0.99 (0.31–3.13)

AA

5300

2

0.64 (0.14–2.83)

0.65 (0.14–3.12)

5301

1

1.19 (0.13–10.69)

1.42 (0.14–13.89)

GnRH

2075

1

0.65 (0.08–5.67)

0.48 (0.05–4.42)

2075

1

3.46 (0.22–55.78)

3.29 (0.18–58.56)

GnRH + Flare

8245

8

1.62 (0.70–3.74)

1.55 (0.62–3.85)

8251

2

1.05 (0.22–4.98)

1.11 (0.23–5.47)

ORCH

1287

2

2.51 (0.42–15.09)

2.45 (0.38–15.70)

1289

0

–

–

TAB

640

0

–

–

640

0

–

–

  1. Multivariable Cox proportional hazard model including marital status (not married, married, separated and widower) and educational level; low (less than 10 years), intermediate (10–12 years) and high educational level (> 12 years).
  2. AA anti-androgens, GnRH gonadotropin releasing hormone, GnRH + Flare gonadotropin releasing hormone + flare protection with AA for a limited time (usually a month), ORCH orchiectomy, TAB total androgen blockade.
Back to article page